Burosumab

Burosumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	FGF 23
Clinical data
Pronunciation	bur OH sue mab
Trade names	Crysvita
Other names	KRN-23, KRN23, burosumab-twza
AHFS/Drugs.com	Monograph
MedlinePlus	a618034
License data	EU EMA: by INN; US DailyMed: Burosumab;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous
ATC code	M05BX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	16.4 days
Identifiers
CAS Number	1610833-03-8;
DrugBank	DB14012;
ChemSpider	none;
UNII	G9WJT6RD29;
KEGG	D10913;
Chemical and physical data
Formula	C6388H9904N1700O2006S46
Molar mass	144090.15 g·mol−1

Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.